Log In
BCIQ
Print this Print this
 

Anti-miR-221

  Manage Alerts
Collapse Summary General Information
Company Regulus Therapeutics Inc.
DescriptionAnti-microRNA-221 (miR-221) oligonucleotide
Molecular Target
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: microRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationLiver cancer
Indication DetailsTreat hepatocellular carcinoma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$35.0M

$120.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/01/2013

Undisclosed

$35.0M

$120.0M

Get a free BioCentury trial today